Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

NMN (nicotinamide mononucleotide)

β-Nicotinamide Mononucleotide (NMN) · also known as NMN, β-NMN, NAD+ precursor

NMN is a direct precursor of NAD+. Human randomized trials have confirmed that oral NMN raises blood NAD+ levels. Whether it drives the sirtuin and PGC-1α pathways in target tissues has not been confirmed in humans, and data on long-term benefit are also very limited.

Typical dose: 250–1000 mg/day, taken in the morning (synergy with resveratrol has not been established).
Absorption and forms: Human RCTs confirmed that oral doses of 250–1000 mg/day raise blood NAD+ levels, but results are mixed on whether skeletal muscle NAD+ rises as well. After oral dosing, a considerable share is dephosphorylated to NR by CD73 in the gut, or converted by gut bacteria to nicotinamide, before being absorbed. A mouse study proposed Slc12a8 as an NMN-specific transporter, but this finding is disputed and has not been confirmed in humans. There is no reliable evidence for the claim that sublingual dosing “bypasses CD38” and works better than capsules.

Clinical uses and human evidence

Blood sugar and insulin resistance

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Yoshino 2021 · Science · RCT · n=25 — Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
  2. Yang 2026 · Nutrients · Meta-analysis — Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis

Endurance performance

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Yi 2023 · Geroscience · RCT · n=80 — The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

Sleep quality

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Kim 2022 · Nutrients · RCT · n=108 — Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study

Fatigue and energy

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Kim 2022 · Nutrients · RCT · n=108 — Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study

Mechanisms of action

Replenishing the NAD+ pool via the salvage pathway

★★★★★Mechanism evidence: grade A

NMN is converted directly to NAD+ by NMNAT1-3 and is a key precursor for NAD+ synthesis. Human randomized trials showed that blood NAD+ rises after oral dosing, but responses differ across tissues and cell compartments, and results in skeletal muscle are inconsistent.

References (2)
  1. Yi 2023 · Human randomized dose trial: oral NMN raised blood NAD levels
  2. Yoshino 2021 · Human randomized trial: studied muscle NAD metabolism and insulin response; a rise in blood NAD does not reflect all tissues

Skeletal muscle GLUT4 translocation and insulin sensitivity

★★★☆☆Mechanism evidence: grade BSecondary target

One randomized controlled trial (25 postmenopausal women with overweight and prediabetes): after 250 mg daily for 10 weeks, muscle insulin sensitivity measured by clamp improved and muscle AKT phosphorylation increased. This is the only study so far, and the finding has yet to be tested in other populations.

References (1)
  1. Yoshino 2021 · Science · RCT · n=25 — Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Sirtuin-dependent protein deacetylase activation

★★★☆☆Mechanism evidence: grade CSecondary target

NAD+ is an essential co-substrate for sirtuin deacetylation reactions, so higher NAD+ is in theory beneficial for sirtuin activity. However, supplying a precursor does not necessarily raise enzyme activity. A mouse study observed SIRT3-dependent protein deacetylation, but direct evidence after oral NMN in humans is still lacking.

References (2)
  1. Klimova 2019 · Mouse intraperitoneal injection study: SIRT3-dependent mitochondrial protein deacetylation was observed
  2. Combined literature assessment · Evidence gap: no reliable human study of oral NMN directly shows that SIRT1, SIRT3 or SIRT6 activity is broadly increased

PGC-1α-driven mitochondrial biogenesis and proliferation

★★☆☆☆Mechanism evidence: grade CSecondary target

NMN could in theory activate PGC-1α through SIRT1-mediated deacetylation. In the heart muscle of SIRT3-deficient mice, NMN increased proteins such as PGC-1α and TFAM. However, a rise in blood NAD+ in humans does not show that mitochondrial numbers increase, so mitochondrial biogenesis in humans has not been confirmed.

References (2)
  1. Zhao 2025 · SIRT3-deficient mouse study: after NMN treatment, heart muscle levels of proteins including PGC-1α and TFAM increased
  2. Yoshino 2021 · Human randomized trial: human metabolic responses alone cannot show PGC-1α deacetylation or mitochondrial biogenesis

Safety and drug interactions

Stopping is advised during active cancer, because active tumor cells may also use NAD+, although this risk is still unclear. Not recommended for pregnant or breastfeeding people. There are not yet enough human data on long-term safety.
Open in the interactive app ›